Dendritic Cell-Based Glioblastoma Vaccines: Advances and Challenges DOI Creative Commons
Zuowen Zhang, Mingchang Li, Jie Huang

et al.

IntechOpen eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Glioblastoma (GBM) is the most aggressive malignancy of central nervous system. Despite advances in standard treatments such as surgery, radiotherapy, and chemotherapy, patients have a very poor prognosis. Tumor vaccines based on dendritic cells (DCs) provide promising new approach for GBM treatment. DCs, effective antigen-presenting cells, initiate adaptive immune responses by activating tumor-specific T cells. However, immunosuppressive microenvironment (characterized regulatory myeloid suppressor factors) physical barrier blood-brain (BBB) greatly limit efficacy DC vaccines. This chapter explores biological basis, preparation process, clinical progress, challenges, future directions DC-based Key aspects antigen selection, vitro culture activation, loading, delivery strategies are analyzed detail. Early trials demonstrated safety potential vaccines, while combination therapies reprogramming being used to overcome existing obstacles. precision personalization highlight their focus immunotherapy research. We believe that with continuous advancement technology interdisciplinary collaboration, can significantly improve survival rate quality life patients.

Language: Английский

Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities DOI Creative Commons
Bolin Wang,

Jinli Pei,

Shengnan Xu

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Sept. 6, 2023

Since the successful application of messenger RNA (mRNA) vaccines in preventing COVID-19, researchers have been striving to develop mRNA for clinical use, including those exploited anti-tumor therapy. cancer emerged as a promising novel approach immunotherapy, offering high specificity, better efficacy, and fewer side effects compared traditional treatments. Multiple therapeutic are being evaluated preclinical trials, with early-phase results. However, development these faces various challenges, such tumor heterogeneity, an immunosuppressive microenvironment, practical obstacles like vaccine administration methods evaluation systems application. To address we highlight recent advances from studies trials that provide insight into identifying associated discuss potential strategies overcome them. In future, it is crucial caution diligence while promoting innovation existing barriers. A delicate balance between opportunities challenges will help guide progress this field towards its full potential.

Language: Английский

Citations

64
Chemistry in phase change energy storage: Properties regulation on organic phase change materials by covalent bond modification DOI
Long Geng,

Jipeng Cui,

Changle Zhang

et al.

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 495, P. 153359 - 153359

Published: June 21, 2024

Language: Английский

Citations

23
Autophagosomes coated in situ with nanodots act as personalized cancer vaccines DOI Creative Commons
Weiqiang Huang, Wei You, Ya-Qi Zhu

et al.

Nature Nanotechnology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Language: Английский

Citations

2
Surface-Engineered Extracellular Vesicles in Cancer Immunotherapy DOI Open Access
Vinith Johnson,

Sunil Vasu,

Uday Kumar Sukumar

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(10), P. 2838 - 2838

Published: May 19, 2023

Extracellular vesicles (EVs) are lipid bilayer-enclosed bodies secreted by all cell types. EVs carry bioactive materials, such as proteins, lipids, metabolites, and nucleic acids, to communicate elicit functional alterations phenotypic changes in the counterpart stromal cells. In cancer, cells secrete shape a tumor-promoting niche. Tumor-secreted mediate communications with immune that determine fate of anti-tumor therapeutic effectiveness. Surface engineering has emerged promising tool for modulation tumor microenvironments cancer immunotherapy. Modification EVs' surface various molecules, antibodies, peptides, can enhance their targeting specificity, immunogenicity, biodistribution, pharmacokinetics. The diverse approaches sought EV surfaces be categorized physical, chemical, genetic strategies. choice method depends on specific application desired outcome. Each its advantages disadvantages. This review lends bird's-eye view recent progress these respect rational implications immunomodulation (TME) from pro-tumorigenic anti-tumorigenic ones. strategies modulating TME using targeted EVs, advantages, current limitations, future directions discussed.

Language: Английский

Citations

35
Cancer vaccines in the clinic DOI Creative Commons

Morgan E. Janes,

Alexander P. Gottlieb,

Kyong Soo Park

et al.

Bioengineering & Translational Medicine, Journal Year: 2023, Volume and Issue: 9(1)

Published: Oct. 27, 2023

Abstract Vaccines are an important tool in the rapidly evolving repertoire of immunotherapies oncology. Although cancer vaccines have been investigated for over 30 years, very few achieved meaningful clinical success. However, recent advances areas such antigen identification, formulation development and manufacturing, combination therapy regimens, indication patient selection hold promise to reinvigorate field. Here, we provide a timely update on status vaccines. We identify critically analyze 360 active trials according delivery vehicle, type, indication, other metrics, as well highlight eight globally approved products. Finally, discuss current limitations future applications translation

Language: Английский

Citations

35
Nanovaccines: An effective therapeutic approach for cancer therapy DOI Open Access
Sangiliyandi Gurunathan, Thangaraj Pratheep, Lin Wang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 170, P. 115992 - 115992

Published: Dec. 9, 2023

Cancer vaccines hold considerable promise for the immunotherapy of solid tumors. Nanomedicine offers several strategies enhancing vaccine effectiveness. In particular, molecular or (sub) cellular can be delivered to target lymphoid tissues and cells by nanocarriers nanoplatforms increase potency durability antitumor immunity minimize negative side effects. Nanovaccines use nanoparticles (NPs) as carriers and/or adjuvants, offering advantages optimal nanoscale size, high stability, ample antigen loading, immunogenicity, tunable presentation, increased retention in lymph nodes, promotion. To induce immunity, cancer rely on tumor antigens, which are administered form entire cells, peptides, nucleic acids, extracellular vesicles (EVs), cell membrane–encapsulated NPs. Ideal stimulate both humoral while overcoming tumor-induced immune suppression. Herein, we review key properties nanovaccines highlight recent advances their development based structure composition various (including synthetic semi (biogenic) nanocarriers. Moreover, discuss cell–derived those whole-tumor-cell components, EVs, NPs, hybrid membrane–coated NPs), nanovaccine action mechanisms, challenges immunocancer therapy translation clinical applications.

Language: Английский

Citations

28
Tumor-derived systems as novel biomedical tools—turning the enemy into an ally DOI Creative Commons
Nimeet Desai, Pratik Katare,

Vaishali Makwana

et al.

Biomaterials Research, Journal Year: 2023, Volume and Issue: 27(1)

Published: Feb. 9, 2023

Cancer is a complex illness that presents significant challenges in its understanding and treatment. The classic definition, "a group of diseases characterized by the uncontrolled growth spread abnormal cells body," fails to convey intricate interaction between many entities involved cancer. Recent advancements field cancer research have shed light on role played individual tumor microenvironment as whole development progression. This breakthrough enables utilization components biological tools, opening new possibilities. article delves deeply into concept "tumor-derived systems", an umbrella term for tools sourced from aid combatting it. It includes cell membrane-coated nanoparticles (for theranostics), extracellular vesicles diagnosis/therapy), lysates vaccine development), engineered cells/organoids research). review seeks offer complete overview tumor-derived materials are utilized research, well their current stages implementation. aimed primarily at researchers working interface biology biomedical engineering, it provides vital insights this fast-growing topic.

Language: Английский

Citations

25
Hybrid Ginseng‐derived Extracellular Vesicles‐Like Particles with Autologous Tumor Cell Membrane for Personalized Vaccination to Inhibit Tumor Recurrence and Metastasis DOI Creative Commons
Haoran Wang,

Jian-Kang Mu,

Yexing Chen

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(17)

Published: Feb. 14, 2024

Abstract Personalized cancer vaccines based on resected tumors from patients is promising to address tumor heterogeneity inhibit recurrence or metastasis. However, it remains challenge elicit immune activation due the weak immunogenicity of autologous antigens. Here, a hybrid membrane vaccine successfully constructed by fusion enhance adaptive response and amplify personalized immunotherapy, which formed codelivery system for antigens adjuvants. Briefly, functional vesicles (HM‐NPs) are hybridizing ginseng‐derived extracellular vesicles‐like particles (G‐EVLPs) with originated tumors. The introduction G‐EVLPs can phagocytosis dendritic cells (DCs) facilitate DCs maturation through TLR4, ultimately activating tumor‐specific cytotoxic T lymphocytes (CTLs). HM‐NPs indeed strengthen specific responses suppress metastasis including subcutaneous orthotopic Furthermore, long‐term protection be obtained after vaccinating HM‐NPs, prolonging survival animals. Overall, this provides possibility mitigating surgery while maintaining good biocompatibility.

Language: Английский

Citations

14
Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy DOI Creative Commons
Muyang Yang, Jie Zhou,

Liseng Lu

et al.

Exploration, Journal Year: 2024, Volume and Issue: 4(6)

Published: March 28, 2024

Abstract Because therapeutic cancer vaccines can, in theory, eliminate tumor cells specifically with relatively low toxicity, they have long been considered for application repressing progression. Traditional containing a single or few discrete epitopes failed the clinic, possibly due to challenges epitope selection, target downregulation, cell heterogeneity, microenvironment immunosuppression, lack of vaccine immunogenicity. Whole membrane vaccines, which provide rich source antigens, are emerging as viable alternatives. Autologous and allogenic cellular evaluated clinical treatments. Tumor membranes (TCMs) an intriguing antigen source, membrane‐accessible targets and, at same time, serve integrated carriers adjuvants other agents. This review provides summary properties technologies TCM vaccines. Characteristics, categories, mechanisms, preparation methods discussed, demonstrable additional benefits derived from combining chemotherapy, sonodynamic therapy, phototherapy, oncolytic viruses. Further research chemistry, biomedicine, immunology, bioinformatics address current drawbacks could facilitate adoption

Language: Английский

Citations

12
Novel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity DOI
Ji-Hoon Han, Seohyun Kim,

Yeong Ha Hwang

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(25)

Published: April 26, 2024

Cancer vaccines offer a promising avenue in cancer immunotherapy by inducing systemic, tumor-specific immune responses. Tumor extracellular vesicles (TEVs) are nanoparticles naturally laden with tumor antigens, making them appealing for vaccine development. However, their inherent malignant properties from the original cells limit direct therapeutic use. This study introduces novel approach to repurpose TEVs as potent personalized vaccines. The shows that inhibition of both YAP and autophagy not only diminishes malignancy-associated traits but also enhances immunogenic attributes enriching load antigens adjuvants. These revamped TEVs, termed attenuated yet immunogenically potentiated (AI-TEVs), showcase potential inhibiting growth, preventive measure possible treatment recurrent cancers. They prompt enduring memory. In addition, showing AI-TEVs can counteract growth approach, strategy is presented developing postoperative that's tailored individual patients.

Language: Английский

Citations

11